DSP-5336

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of DSP-5336 Following a Single Oral Dose in Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Myeloproliferative Neoplasms

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
8 patients (estimated)
Tags
Menin Inhibitor
Trial Type
Treatment
Last Update
SparkCures ID
2250
NCT Identifier
NCT07444268

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.